Anti-Obesity Drugs Market
According to Intent Market Research, the Anti-Obesity Drugs Market is expected to grow from USD 6.2 billion in 2023 at a CAGR of 28.5% to touch USD 35.9 billion by 2030. The Anti-Obesity Drugs Market is dominated by key players such as Novo Nordisk, Eli Lilly and Company, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer Inc., Orexigen Therapeutics, Sanofi S.A., AstraZeneca, Roche, AbbVie, Johnson & Johnson, Amgen Inc., Bayer AG, Mylan N.V., Allergan